Ngā hua rapu - N. Reguart
- E whakaatu ana i te 1 - 3 hua o te 3
-
1
1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose dise... mā Helena A. Yu, Helen Ambrose, Christina S. Baik, B.C. Cho, Emiliano Cocco, Sarah B. Goldberg, Jonathan W. Goldman, Silvija Kraljevic, Adrianus J. de Langen, Isamu Okamoto, Zofia Piotrowska, Michael Pluta, S. Powar, N. Reguart Aransay, Jonathan W. Riess, Xiuning Le
I whakaputaina 2021Artigo -
2
PL03.12 Progression Free Survival and Overall Survival in NADIM II Study mā M. Provencio, R. Serna, E. Nadal, J.L. Glez Larriba, Alex Martínez‐Martí, R. Bernabé, J. Bosch-Barrera, C. Garcia Benito, V. Calvo, A. Insa, Sofia Ivonny Castro Ponce, N. Reguart, J. De Castro, B. Massutí, R. Palmero, Carlos Aguado, J. Mosquera, M. Cobo, Andy Aguilar, Guillermo López-Vivanco, C. Camps, Florentino Hernándo, Rafael López Castro, T. Moran, I. Barneto, D. Rodríguez-Abreu, A. Romero
I whakaputaina 2022Artigo -
3
Pooled safety analysis and management of sotorasib-related adverse events in <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer mā Ferdinandos Skoulidis, Bob T. Li, Maximilian J. Hochmair, Ramaswamy Govindan, Mark Vincent, Anthonie J. van der Wekken, N. Reguart Aransay, Kenneth J. O’Byrne, Nicolas Girard, Frank Griesinger, Makoto Nishio, Simon Häfliger, Colin R. Lindsay, Niels Reinmuth, Astrid Paulus, Pavlos Papakotoulas, Sang‐We Kim, Carlos Gil Ferreira, Giulia Pasello, M. Duruisseaux, Spyridon Gennatas, Anastasios Dimou, Bhakti Mehta, William Kormany, Chidozie Nduka, Brooke E. Sylvester, Christine Ardito-Abraham, Yang Wang, Adrianus J. de Langen
I whakaputaina 2025Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Internal medicine
Medicine
Oncology
Cancer
Lung cancer
A549 cell
Adenocarcinoma
Adverse effect
Biochemistry
Biomarker
Cancer research
Chemistry
Clinical trial
Colorectal cancer
Interim analysis
KRAS
Meta-analysis
Osimertinib
Overall survival
Pooled analysis
Progression-free survival
ROS1
Survival analysis
non-small cell lung cancer (NSCLC)